Please use this identifier to cite or link to this item:
|Title:||Microbial transformation of nandrolone with Cunninghamella echinulata and Cunninghamella blakesleeana and evaluation of leishmaniacidal activity of transformed products||Authors:||Baydoun, Elias A-H.
Khan, Mahwish Shafi Ahmed
Ahmad, Malil Shoaib
Choudhary, Muhammad Iqbal
|Affiliations:||Department of Biology||Keywords:||Anabolic compound
|Subjects:||Nandrolone||Issue Date:||2014||Part of:||Steroids||Volume:||88||Start page:||95||End page:||100||Abstract:||
Therapeutic potential of nandrolone and its derivatives against leishmaniasis has been studied. A number of derivatives of nandrolone (1) were synthesized through biotransformation. Microbial transformation of nandrolone (1) with Cunninghamella echinulata and Cunninghamella blakesleeana yielded three new metabolites, 10β,12β,17β-trihydroxy-19-nor-4-androsten-3-one (2), 10β,16α,17β-trihydroxy-19-nor-4-androsten-3-one (3), and 6β,10β,17β-trihydroxy-19-nor-4-androsten-3-one (4), along with four known metabolites, 10β,17β-dihydroxy-19-nor-4-androsten-3-one (5), 6β,17β-dihydroxy-19-nor-4-androsten-3-one (6) 10β-hydroxy-19-nor-4-androsten-3,17-dione (7) and 16β,17β-dihydroxy-19-nor-4-androsten-3-one (8). Compounds 1–8 were evaluated for their anti-leishmanial activity. Compounds 1 and 8 showed a significant activity in vitro against Leishmania major. The leishmanicidal potential of compounds 1–8 (IC50 = 32.0 ± 0.5, >100, 77.39 ± 5.52, 70.90 ± 1.16, 54.94 ± 1.01, 80.23 ± 3.39, 61.12 ± 1.39 and 29.55 ± 1.14 μM, respectively) can form the basis for the development of effective therapies against the protozoal tropical disease leishmaniasis.
|URI:||https://scholarhub.balamand.edu.lb/handle/uob/2243||DOI:||10.1016/j.steroids.2014.06.020||Ezproxy URL:||Link to full text||Type:||Journal Article|
|Appears in Collections:||Department of Biology|
Show full item record
checked on May 8, 2021
checked on May 9, 2021
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.